Huntington’s Disease

Advancing Huntington's Disease Research

We are a leading provider of specialist medical imaging and digital biomarker analysis for Huntington’s disease research. Huntington’s disease is a highly specialist area of clinical research. Currently, we are providing advanced imaging analytics for numerous ongoing Huntington’s disease drug trials.

We understand that neuroimaging requirements often change throughout the course of Huntington’s disease drug trials. We are able to respond to this by providing reproducible, regulatory compliant data, in-depth analysis and expert insight across all phases of your HD clinical trial.

We are committed to advancing research to find a treatment for Huntington’s disease. We are working alongside the Huntington’s Disease Regulatory Science Consortium (HD-RSC) to review current evidence, identify evidence gaps and plan targeted research with the potential to increase the efficiency, safety, and speed of drug development to find new HD treatments.

Proven track record

  • We played a pivotal role in standardising the acquisition of MRI data and characterising imaging biomarkers for Huntington’s disease during the TRACK-HD and Track-On HD prospective observational biomarker studies.
  • This work validated the Brain Boundary Shift Integral (BSI) image analysis technology as a method to measure whole brain, ventricle volume and atrophy in HD patients.

Expert consultancy

  • Our highly qualified team understand HD biology and deploy novel imaging techniques including advanced MRI, PET, and digital biomarkers via wearables for reproducible analytics through all study phases in Huntington's disease research.
  • Through fully compliant, scalable operational processes, we have delivered globally over 100 CNS clinical trials, including 16 in HD clinical trials 9 of which are current studies.

Vital collaboration

  • We collaborate with international consortia, academic institutions and global networks of research sites who are committed to advancing Huntington’s disease research.
  • We have partnered with the Critical Path consortia HD-RSC to help develop new, regulatory-endorsed drug development tools that will improve the clinical trial process and regulatory path for emerging HD therapies, de-risking the development of new treatments.


Patient focus

  • We are truly patient-centric, combining insight into people living with Alzheimer’s disease with training and technology to improve recruitment, retention and support for Huntington’s disease clinical trial participants.

Whatever we ask for, IXICO has accommodated. We have had to change directions often and I am very happy with how things are going. I don’t think we could get anyone better in Huntington’s disease.

Clinical Director, Neuroscience - Pharma Client

We offer comprehensive neuroimaging solutions to support with patient eligibility, stratification, drug safety monitoring and efficacy assessment in Huntington's disease clinical trials.

About Huntington's Disease

Huntington’s disease (HD) is a rare, genetic progressive disorder that affects an individual’s behavioral, cognitive and motor functions. HD causes degeneration of the nerve cells in the brain, resulting in a significant and devastating impact in the patients’ ability to think, feel, behave and move. HD is caused by a mutation in a single gene (“HTT”), which triggers the formation of toxic protein (“mHTT”) and therefore, unlike diseases such as Alzheimer’s disease, we know exactly what causes HD.

Affecting men and women equally, symptoms usually start between 30-50 years of age but can develop earlier in children and teenagers. HD gradually worsens over time,  and sadly somewhere between 10 and 25 years after symptoms first appear, HD is usually fatal due to complications often involving pneumonia, heart failure or other conditions. According to the World Health Organization, in the Western world, 5-7 people per 100,000 are affected with HD, with more at risk of developing the disease at some stage in their life due to genetic predisposition. 

IXICO has an unrivalled and unique track record in Huntington's disease clinical research, having supported 14 clinical trials for this rare indication and currently supporting the largest ongoing HD trial. 

Find out more about Huntington's disease